194 related articles for article (PubMed ID: 37886029)
21. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
Huang T; He Y; Yu C; Mao F; Si Y
Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
[TBL] [Abstract][Full Text] [Related]
22. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
[TBL] [Abstract][Full Text] [Related]
23. The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Meegdes M; Geurts SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Teeuwen NJA; de Boer M; Tjan-Heijnen VCG
Int J Cancer; 2022 Jan; 150(1):124-131. PubMed ID: 34460112
[TBL] [Abstract][Full Text] [Related]
24. Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience.
Decker T; Seifert R; Bichler M; Birtel A; Fischer G; Nonnenbroich C; Dechow T
Oncol Res Treat; 2021; 44(9):443-449. PubMed ID: 34350900
[TBL] [Abstract][Full Text] [Related]
25. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
26. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
28. Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
Kim KN; Shah P; Clark A; Freedman GM; Dastgheyb S; Barsky AR; Dreyfuss AD; Taunk NK
Breast; 2021 Dec; 60():163-167. PubMed ID: 34653725
[TBL] [Abstract][Full Text] [Related]
29. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
[TBL] [Abstract][Full Text] [Related]
30. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N
Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():3-11. PubMed ID: 30288930
[TBL] [Abstract][Full Text] [Related]
31. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
32. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
34. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
35. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.
Loibl S; Furlanetto J
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S70-S79. PubMed ID: 34930649
[TBL] [Abstract][Full Text] [Related]
36. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
37. Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.
Kitano S; Honda A; Itoi N; Lee T
Anticancer Res; 2022 Aug; 42(8):3913-3919. PubMed ID: 35896230
[TBL] [Abstract][Full Text] [Related]
38. Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Fontanella C; Giorgi CA; Russo S; Angelini S; Nicolardi L; Giarratano T; Frezzini S; Pestrin M; Palleschi D; Bolzonello S; Parolin V; Haspinger ER; De Rossi C; Greco F; Gerratana L
Crit Rev Oncol Hematol; 2022 Dec; 180():103848. PubMed ID: 36257536
[TBL] [Abstract][Full Text] [Related]
39. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
[TBL] [Abstract][Full Text] [Related]
40. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]